Company description
IMS Health is the world’s leading information, services and technology company dedicated to making healthcare perform better. Drawing on information from 100,000 suppliers, and on insights from more than 45+ billion healthcare transactions processed annually, IMS Health’s 9,000+ expert resources drive results for over 5,000 healthcare clients globally. They are present in Poland since 1991 and have developed insightful market knowledge and grown a team of local experts. Their customers include pharmaceutical, medical device and consumer health manufacturers and distributors, providers, payers, government agencies, and the financial community.
By applying cutting-edge analytics and proprietary application suites hosted on the IMS One intelligent cloud, the company connects more than 10 petabytes of complex healthcare data on diseases, treatments, costs and outcomes to enable their clients to run their operations more efficiently.
Address:
IMS Poland Ltd.
Sp. z o.o. ul.
ul. Konstruktorska 13 /
02 – 673 Warszawa
Poland
Tel: +48 22 598 03 00
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
IMS ‘lives and breathes the pharma industry’ and it is stimulating to come from other forms of consultancy to IMS. You have worked in various businesses. What motivated you to…
Poland has an important manufacturing role for the CEE region and this is where Mylan has settled Agila, a state-of-the-art, high quality injectables manufacturing platform. Mylan has great ambitions in…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
GSK Poland’s General Manager, Jerzy Toczyski, explains the reasons behind acquiring a state-of-the-art manufacturing facility in Poland, as well as the need to implement leaner manufacturing processes to become more…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Sanofi’s General Manager in Poland, Marynika Woroszylska-Sapieha, shares two very important concepts that showcase the situation in Poland, stating that: “The biggest obstacle to innovation in Poland is the threshold…
“Average pharmaceutical company expenditures on R&D are in the range of 13 to 15 percent of revenues: much higher than the global average, and much higher than other Polish industrial…
“The swelling influence of wholesalers in the market frightens me.” With three wholesalers in Poland holding 80 percent of the market and establishing their own brands in a changing environment,…
“Instead of creating a state pharmaceutical duopoly, we have created an environment where the pharma industry can introduce new products and market them enthusiastically. This creates a market where pharmaceutical…
Persistence is a blessing, explains Glenmark’s Country Manager for Poland, Andrzej Gondek. By adapting a new product strategy to increase their OTC portfolio, Glenmark managed to nearly double its sales…
See our Cookie Privacy Policy Here
